In pancreatic cancer, an extremely aggressive tumor which accounts for about 7% of all cancer deaths in the United States, EphA2 overexpression is inversely correlated with patient survival [5,21]. This evidence concerns the gene EPHA2 and familial pancreatic carcinoma.